Evidence map›Paper›PMID 40852486›Full record

ArticleFrontiers in oncology2025

Case Report: Application of

Philip K Tan, Timothy J Martins, Pamela S Becker, Robert J Wechsler-Reya, John Ross Crawford

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Philip K TanThe Cure Starts Now Foundation, Cincinnati, OH, United States.
Timothy J MartinsInstitute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle, WA, United States.
Pamela S BeckerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States.
Robert J Wechsler-ReyaCancer Genome and Epigenetics Program, National Cancer Institute (NCI)-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
John Ross CrawfordRady Children's Hospital, San Diego, CA, United States.

Funding

Identifying and Targeting the Drivers of Pediatric Brain TumorsR35NS122339 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 to 2025
$1.1M
NINDS NIH HHS R35 NS122339
6 · The paper itself

Abstract

Diffuse midline glioma (DMG) is a pediatric brain cancer that has a dismal prognosis with limited treatment options. We present the treatment course and outcome of an adolescent male diagnosed with a thalamic DMG carrying a histone H3.3 K27M (H3K27M) alteration. Tumor biopsies were taken at diagnosis for histological analysis, molecular profiling, and

Indexed as

diffuse midline gliomadrug sensitivity testingfunctional precision medicinemolecular guided therapypediatric brain cancer

Identifiers

PMID40852486
PMCPMC12367499

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.